Missed Phase II endpoint but promising signs for tivantinib in colorectal cancer
This article was originally published in Scrip
ArQule's lead product candidate tivantinib (ARQ 197) has hit another bump on its road to market, this time in the colorectal cancer setting where it has missed the primary endpoint in a Phase II international trial.
You may also be interested in...
Japanese firm says it will end SHP647 development after trying unsuccessfully to find takers for GI drug similar to its blockbuster Entyvio, first flagged by European authorities over competition worries.
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.